As you guys have written about before, the Kevetri

As you guys have written about before, the Kevetrin patent is written with the thought in mind for many indications and formulations.  Kevetrin has ten to 20 years, or more of catalysts built into it due to this reason, and in order to maximize CTIX shareholder value, they need to go to NASDAQ. The cost of compliance is minimal compared to the benefits and access to capital/partnerships etc. etc.  A no brainer, and besides, they already have uplisted from the pinks to otcbb.

I see CTIX as a cash machine collecting royalties, milestone payments etc and  farming out the partnerships for multitudes of indications of Kevetrin to companies with established field sales forces.  Though anything is possible, that's what I see.